E

Editas Medicine

CRISPR-based gene editing therapeutics developer

Vice President, Regulatory Affairs

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeCambridge, MA, USA$345k - $372kHybrid

About the Job

Requirements

  • An advanced degree in a scientific, medical, pharmacy, engineering, or related discipline is strongly preferred; a bachelor's degree with substantial directly relevant experience is considered.
  • At least 15 years of progressive experience in biotechnology or pharmaceutical Regulatory Affairs, including serving as the senior-most regulatory professional in a small or emerging company and personally executing regulatory work with limited internal infrastructure.
  • Demonstrated ownership of global regulatory strategy and major submissions for innovative therapeutics, including authoring and assembling key submission documents, leading FDA interactions, and working with other major health authorities.
  • Experience advancing programs from preclinical development into and through clinical development; late-stage development or marketing application experience is strongly valued.
  • Deep knowledge of global drug development regulations and guidance, integrating clinical, nonclinical, chemistry, manufacturing and controls, safety, quality, and benefit-risk considerations into a coherent regulatory position.
  • Experience with in vivo genetic medicines, rare or genetic diseases, orphan-drug development, expedited programs, and innovative or biomarker-driven clinical development.
  • Experience addressing long-term follow-up, genomic safety, immunogenicity, biodistribution, durability, potency, comparability, and evolving regulatory expectations for advanced therapies.
  • Ability to work effectively as an individual contributor while managing external regulatory, publishing, medical writing, and consulting resources.
  • Experience in a small or emerging biotechnology company, including building a regulatory function, supporting Board and investor communications, and operating across internal and partnered programs.
  • Working knowledge of electronic Common Technical Document (eCTD) structure and submission workflows, regulatory information management and document-management systems, submission publishing, regulatory calendars, health-authority correspondence, commitments tracking, and scalable document-governance practices.
  • Experience with CRISPR or other gene-editing therapeutics, gene therapy, RNA therapeutics, messenger RNA (mRNA), RNA interference (RNAi), lipid nanoparticle (LNP) delivery, or other advanced modalities may be considered.
  • Exceptional executive communication, scientific judgment, negotiation, influence, organizational leadership, and decision-making skills.
  • Ability to move between executive-level strategy and detailed execution while balancing speed, scientific innovation, patient safety, regulatory credibility, and long-term value creation.

Responsibilities

  • Define and execute an integrated global regulatory strategy across the portfolio, aligning regulatory pathways, development plans, resources, risks, and key decision points with corporate priorities.
  • Lead regulatory strategy from preclinical development through first-in-human studies, proof of concept, registrational development, and marketing applications, including Investigational New Drug (IND) applications, Clinical Trial Applications (CTAs), expedited and special designation requests, and future Biologics License Applications (BLAs) and Marketing Authorisation Applications (MAAs).
  • Provide regulatory recommendations, scenario analyses, and risk-mitigation plans to governance bodies and executive leadership; escalate material issues early and drive timely, evidence-based decisions.
  • Serve as the senior regulatory representative and primary day-to-day contact in interactions with the Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and other health authorities. Lead briefing strategy, meeting preparation, rehearsal, negotiation, agency correspondence, responses, commitments, and follow-through.
  • Anticipate and address gene-editing-specific issues, including editing specificity and off-target assessment, genomic integrity, biodistribution and persistence, immunogenicity, delivery-platform risks, long-term follow-up, durability, and chemistry, manufacturing and controls (CMC) comparability.
  • Monitor global policy, guidance, advisory committee activity, and competitive precedent in gene editing, gene therapy, rare disease, and advanced therapeutics, and translate developments into actionable portfolio strategy.
  • Partner with Clinical Development, Clinical Operations, Bioanalytics, CMC, Nonclinical, Translational Medicine, Quality, Safety, Legal, and Program Management to ensure development plans and evidence packages are scientifically rigorous, operationally feasible, and regulatory-ready.
  • Plan, author, coordinate, compile, review, and drive the on-time delivery of regulatory submissions and communications, including INDs and CTAs, amendments, annual reports, safety reports, meeting requests and briefing packages, designation requests, responses to information requests, and other agency correspondence.
  • Own submission-level project management by defining content plans, author assignments, review cycles, dependencies, timelines, readiness checks, approvals, publishing handoffs, and filing confirmation.
  • Draft and edit core regulatory documents and integrate cross-functional source content into a clear, consistent company position; identify content gaps, resolve comments, and maintain version and change control.
  • Manage routine regulatory operations, including agency correspondence, regulatory intelligence, submission and commitment tracking, document archiving, vendor oversight, and maintenance of the regulatory history for each program.
  • Lead product-quality regulatory strategy and execution, working with CMC and Quality colleagues to develop submission content addressing control strategy, potency, specifications, analytical validation, manufacturing changes, comparability, and lifecycle considerations for gene-editing components and delivery systems.
  • Establish and operate a fit-for-purpose Regulatory Affairs function as the sole internal regulatory professional initially. Create practical processes, templates, submission plans, regulatory calendars, correspondence and commitment trackers, document standards, and governance routines; manage consultants and vendors selectively while retaining direct ownership of the work.
  • Lead regulatory assessment and strategy for business development, alliances, licensing, and partnered programs, including diligence, governance, and alignment of responsibilities and regulatory positions.
  • Maintain inspection-ready regulatory documentation, health-authority correspondence, submission archives, governance records, commitments, and regulatory systems. Partner with Quality to develop appropriate procedures, support Good Practice (GxP) compliance, and prepare for health-authority inspections.
  • Represent the company in appropriate external forums and communicate complex regulatory issues to scientific, clinical, executive, Board, partner, and investor audiences.

Desired Qualifications

  • Direct regulatory experience with CRISPR or other gene-editing therapeutics is preferred; relevant experience in gene therapy, RNA therapeutics, mRNA, RNA interference (RNAi), lipid nanoparticle (LNP) delivery, or other advanced modalities may also be considered.
  • Late-stage development or marketing application experience is strongly valued.
  • Prior team-building experience is valued.

About the Company

Editas Medicine

CRISPR-based gene editing therapeutics developer

Editas Medicine develops therapies using CRISPR gene-editing to treat serious diseases. The company advances a pipeline of genomic medicines by discovering, developing, manufacturing, and aiming to commercialize these gene-editing treatments. CRISPR allows scientists to modify DNA in cells to correct genetic defects, and Editas combines this approach with clinical development to bring potential medicines to patients. Unlike firms that focus on other biotechnologies, Editas emphasizes a full drug-development cycle centered on CRISPR-based genomic medicines and partnerships to expand its reach. The company’s goal is to deliver durable, transformative treatments that improve patient outcomes worldwide by moving candidates from discovery through trials to potential approval and commercialization.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2013

Recently Posted Jobs

Explore more opportunities at Editas Medicine

See more jobs